Astellas Receives U.S. FDA Fast Track Designation for ASP5354, an Investigational Near-Infrared Fluorescence Imaging Agent

TOKYO, Oct. 28, 2020 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., " Astellas " ) announced today that the United States ( " U.S. " ) Food and Drug Administration (FDA) has granted...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials